Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine

17 May 2022

Abstract excerpt

BACKGROUND: There is an urgent need of a new generation of vaccine that are able to enhance protection against SARS-CoV-2 and related variants of concern (VOC) and emerging coronaviruses. METHODS: We identified conserved T- and B-cell epitopes from Spike (S) and Nucleocapsid (N) highly homologous to 38 sarbecoviruses, including SARS-CoV-2 VOCs, to design a protein subunit vaccine targeting antigens to Dendritic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35594660
DOI: 10.1016/j.ebiom.2022.104062

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccinePMID 35594660Read ↗

Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccineSemantic proximity Read ↗

A conserved region T-cell vaccine for SarbecovirusesSemantic proximity Read ↗

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-cell VaccineSemantic proximity Read ↗

A Single Chimeric Spike Antigen Induces Pan-Sarbecovirus ImmunitySemantic proximity Read ↗

UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of ConcernSemantic proximity Read ↗

Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validationSemantic proximity Read ↗

Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum ProtectionSemantic proximity Read ↗

T cell-mediated protection against lethal SARS-CoV-2 challenge by a synthetic long peptide vaccine targeting conserved CD4+ and CD8+ T cell epitopesSemantic proximity Read ↗

A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross- Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 VariantsSemantic proximity Read ↗

Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing AntibodiesSemantic proximity Read ↗

Targeting Multiple Conserved T-Cell Epitopes for Protection against COVID-19 Moderate-Severe Disease by a Pan-Sarbecovirus VaccineSemantic proximity Read ↗

Identification of SARS-CoV-2 Vaccine Epitopes Predicted to Induce Long-Term Population-Scale ImmunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.